People
The governance grade is B: Cigna has a seasoned board and credible internal CEO succession, but PBM/regulatory conduct issues, limited insider ownership beyond Cordani, and shareholder-rights tension cap the grade.
The People Running This Company
David Cordani - CEO to Executive Chair
▲ 1,204,028 Beneficial shares
Brian Evanko - Incoming CEO
▲ 167,014 Beneficial shares
Ann Dennison - CFO
▲ 8,464 Beneficial shares
Nicole Jones - CAO and GC
▲ 104,223 Beneficial shares
Cigna is not founder-controlled. The people case rests on institutional depth: a long-tenured outgoing CEO, an internal successor with finance and operating credentials, and a board that says it ran a multi-year succession process with an external search firm. The main question is whether Evanko can execute the PBM business-model pivot while Cordani's Executive Chair role preserves, rather than mutes, independent oversight.
What They Get Paid
Pay is high, but not obviously detached from a company with $274.9B of 2025 revenue and $8.0B of adjusted income from operations. The better sign is structure: the proxy says 92% of Cordani's target pay was performance-based, the 2023-2025 strategic performance share award paid at 73% of target, and Cordani's 2025 annual incentive paid at 100% of target rather than above target. The concern is transition pay: Cordani remains eligible for Executive Chair compensation and LTI, while Evanko's CEO package includes a $15.1M LTI target and a one-time $3.5M transitional equity award.
Are They Aligned?
Skin-in-the-game score
Directors and officers ownership
Cordani beneficial shares
2025 buybacks
Alignment is financially decent, not pristine. The latest proxy reports no disclosable related-person transactions and no pledged shares, but the conduct record includes the 2026 Express Scripts FTC insulin settlement and the 2023 Medicare Advantage risk-adjustment settlement for approximately $172M.
The skin-in-the-game score is 7/10. Cordani's stake is real and ownership guidelines are strong: 8x salary for the CEO, 6x for Evanko, and 3x for other named executives, with hedging and pledging prohibited. The score stops short of excellent because directors and officers as a group own only 0.6%, recent open-market insider activity skewed toward selling, and alignment depends more on compensation design and buybacks than broad insider capital at risk. No warrant overhang was found; option awards remain a normal part of LTI and stock issuance has been more than absorbed by repurchases. Cigna also says it has no written related-person transaction policy; because the 2025 review found no disclosable related-person transactions, this is a process yellow flag rather than evidence of self-dealing.
Board Quality
The board is capable on paper: 10 of 12 nominees are independent, all key committees are independent, and the mix includes health policy, provider operations, audit, cyber, technology, and large-company CEO experience. The weakness is structural rather than personnel-based. Cordani's move to Executive Chair keeps a powerful former CEO in the boardroom, two independent directors have tenure of roughly two decades, and the 2026 shareholder proposal for written consent drew about 48% support among votes for and against, which means shareholder-rights dissatisfaction is economically relevant rather than cosmetic.
The Verdict
Skin-in-the-game score
2026 say-on-pay support
Written-consent support
The strongest positive is controlled succession: Evanko is a credible internal operator, the board has relevant industry and technology expertise, and executive pay is mostly at risk rather than salary-heavy.
The real concern is conduct and accountability: PBM pricing pressure, FTC settlement obligations, past Medicare Advantage settlement history, and a near-majority shareholder vote for written consent all argue against a higher grade today.
The likely upgrade would come from Evanko proving the rebate-free PBM transition can be executed with transparent economics, fewer regulatory surprises, and clearer independent-board authority around the Executive Chair. The likely downgrade would be another large conduct settlement, material PBM transition miss, or evidence that the board ignores shareholder-rights pressure while keeping too much practical control with the former CEO.